Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Drusano

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 1997
Meropenem: laboratory and clinical dataGeorge Drusano
Antibiotics (Basel, Switzerland)|November 24, 2023
Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative SepsisAlwin Tilanus, George Drusano
Open Forum Infectious Diseases|July 7, 2023
Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of TimeAlwin Tilanus, George Drusano
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 19, 2021
Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients FirstThomas P Lodise, George Drusano
The Journal of Antimicrobial Chemotherapy|April 12, 2021
The case for precision dosing: medical conservatism does not justify inactionMarc H Scheetz, Thomas P Lodise, Kevin J Downes, et al.
The Journal of Antimicrobial Chemotherapy|November 16, 2019
In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeaeSunniva Foerster, George Drusano, Daniel Golparian, et al.
Frontiers in Pharmacology|May 2, 2022
Pharmacodynamic Evaluation of Zoliflodacin Treatment of <i>Neisseria gonorrhoeae</i> Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection ModelSusanne Jacobsson, Daniel Golparian, Joakim Oxelbark, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2024
Omadacycline is active <i>in vitro</i> and <i>in vivo</i> against ciprofloxacin-resistant <i>Bacillus anthracis</i>Henry S Heine, George Drusano, Bret K Purcell, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 4, 2025
Analyzing Pharmacodynamic Count Data That Rapidly Decrease to ZeroWalter M Yamada, Alan Schumitzky, Alona Kryshchenko, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2024
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoeaMagnus Unemo, Daniel Golparian, Joakim Oxelbark, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 1997
Meropenem: laboratory and clinical dataGeorge Drusano
Antibiotics (Basel, Switzerland)|November 24, 2023
Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative SepsisAlwin Tilanus, George Drusano
Open Forum Infectious Diseases|July 7, 2023
Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of TimeAlwin Tilanus, George Drusano
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 19, 2021
Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients FirstThomas P Lodise, George Drusano
The Journal of Antimicrobial Chemotherapy|April 12, 2021
The case for precision dosing: medical conservatism does not justify inactionMarc H Scheetz, Thomas P Lodise, Kevin J Downes, et al.
The Journal of Antimicrobial Chemotherapy|November 16, 2019
In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeaeSunniva Foerster, George Drusano, Daniel Golparian, et al.
Frontiers in Pharmacology|May 2, 2022
Pharmacodynamic Evaluation of Zoliflodacin Treatment of <i>Neisseria gonorrhoeae</i> Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection ModelSusanne Jacobsson, Daniel Golparian, Joakim Oxelbark, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2024
Omadacycline is active <i>in vitro</i> and <i>in vivo</i> against ciprofloxacin-resistant <i>Bacillus anthracis</i>Henry S Heine, George Drusano, Bret K Purcell, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 4, 2025
Analyzing Pharmacodynamic Count Data That Rapidly Decrease to ZeroWalter M Yamada, Alan Schumitzky, Alona Kryshchenko, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2024
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoeaMagnus Unemo, Daniel Golparian, Joakim Oxelbark, et al.
Pageof 3